论文部分内容阅读
目的:探讨血清总PSA(TPSA)、F/TPSA和PSA密度(PSAD)在前列腺癌(PCa)诊断中的价值,寻找更准确的前列腺癌诊断指标。方法:采用化学发光免疫分析法检测前列腺癌患者(60例)和前列腺增生患者(240例)的血清PSA水平,通过B超测定患者前列腺的体积,计算PSAD,运用ROC曲线评价和比较血清总PSA(TPSA)、F/TPSA和PSAD诊断前列腺癌的准确性和特异性。结果:(1)前列腺癌患者TPSA和PSAD值均明显高于前列腺增生患者(P<0.01),F/TPSA明显低于前列腺增生患者(P<0.01);(2)TPSA阈值定为4 ng/ml时,诊断前列腺癌的敏感性、特异性分别为56.23%、80.10%。F/TPSA阈值定为0.15时,诊断前列腺癌的敏感性、特异性分别为88.10%、69.10%,PSAD阈值定为0.20时,诊断前列腺癌的敏感性、特异性分别为88.60%、88.30%。结论:TPSA、F/TPSA和PSAD在前列腺癌诊断中均有一定的价值,且PSAD诊断前列腺癌的敏感性、特异性优于TPSA、F/TPSA,是诊断前列腺癌更为理想的指标。
Objective: To investigate the value of serum total PSA (TPSA), F / TPSA and PSA density (PSAD) in the diagnosis of prostate cancer (PCa) and to find a more accurate diagnosis of prostate cancer. Methods: The levels of serum PSA in prostate cancer (60 cases) and benign prostatic hyperplasia (240 cases) were detected by chemiluminescence immunoassay. The volume of prostate was measured by B ultrasound to calculate the PSAD. The ROC curve was used to evaluate the serum total PSA (TPSA), F / TPSA and PSAD to diagnose the accuracy and specificity of prostate cancer. Results: (1) TPSA and PSAD in patients with prostate cancer were significantly higher than those in patients with benign prostatic hyperplasia (P <0.01), and F / TPSA was significantly lower in patients with prostatic hyperplasia (P <0.01); (2) ml, the sensitivity and specificity of diagnosing prostate cancer were 56.23% and 80.10% respectively. The sensitivity and specificity of diagnosing prostate cancer were 88.10% and 69.10% respectively when the F / TPSA threshold value was 0.15, and the sensitivity and specificity of diagnosing prostate cancer were 88.60% and 88.30% respectively when the threshold value of PSAD was 0.20. Conclusion: TPSA, F / TPSA and PSAD are both valuable in the diagnosis of prostate cancer. PSAD is superior to TPSA and F / TPSA in the diagnosis of prostate cancer, which is a more ideal indicator for the diagnosis of prostate cancer.